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Abstract
The identification of disease-causing genes is a fundamental challenge in human health and of great importance in
improving medical care, and provides a better understanding of gene functions. Recent computational approaches based
on the interactions among human proteins and disease similarities have shown their power in tackling the issue. In this
paper, a novel systematic and global method that integrates two heterogeneous networks for prioritizing candidate
disease-causing genes is provided, based on the observation that genes causing the same or similar diseases tend to lie
close to one another in a network of protein-protein interactions. In this method, the association score function between a
query disease and a candidate gene is defined as the weighted sum of all the association scores between similar diseases
and neighbouring genes. Moreover, the topological correlation of these two heterogeneous networks can be incorporated
into the definition of the score function, and finally an iterative algorithm is designed for this issue. This method was tested
with 10-fold cross-validation on all 1,126 diseases that have at least a known causal gene, and it ranked the correct gene as
one of the top ten in 622 of all the 1,428 cases, significantly outperforming a state-of-the-art method called PRINCE. The
results brought about by this method were applied to study three multi-factorial disorders: breast cancer, Alzheimer disease
and diabetes mellitus type 2, and some suggestions of novel causal genes and candidate disease-causing subnetworks were
provided for further investigation.
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Introduction
Computational investigation of gene functions in the context of
complex biological systems is promoted greatly by the accumulation
of high-throughput data, of which protein-protein interaction data
have been exploited to identify disease-causing genes, based on the
observation that genes implicated in a specific or similar diseases
tend tobe located inaspecificneighbourhood intheprotein-protein
interaction network[1,2,3].Theidentificationofgenes involved ina
specific disease has long been a challenge in the study of human
genetics. In addition to traditional gene-mapping approaches, many
computational methods based on gene functions have appeared,
which was reviewed by Oti and Brunner in [3]. Recently, a few
computational approaches for candidate gene prioritization have
been developed which exploit both the protein-protein interactions
and the disease phenotypic similarities. Lage et al. [4] scored a
candidate protein based on the involvement of its direct network
neighbours involved in a similar disease, in which a new disease
similarity measure was also given and applied for prioritizing both
the protein complex and the candidate disease gene in the protein
complex. Kohler et al. [5] presented a method for prioritization of
candidate genes by use of a global network distance measure-
random walk analysis-for definition of similarities in the protein-
protein interaction network.Wu etal. [6] proposed a computational
framework that integrates human protein-protein interactions,
phenotype similarities, and known gene-phenotype associations to
capture the complex relationships between disease phenotypes and
genotypes. They defined the global concordance score between the
phenotype similarity profile and the gene closeness profile as the
disease-gene association score. Furthermore, a tool named CI-
PHER was developed to predict and prioritize candidate disease-
causing genes. In their follow-up work [7], they studied the
consistency between the disease phenotypic overlap and genetic
overlap via the network alignment technique systematically and
quantitatively. Vanunu et al. introduced PRINCE [8], a global
method for prioritizing candidate genes that simulates a process
where proteins for which prior information exists pump information
to their neighbours in the protein-protein interaction network. In
PRINCE, for a given disease the prioritization is done iteratively
over the entire protein interaction network, and each protein
propagates the information received in the previous iteration to its
neighbours.
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ing candidate disease-causing genes based on exploiting the
protein-protein interaction network and phenotype similarities,
most of which deal with the disease-gene association score based
on the association between the diseases similar to the query
disease and their involved genes independently. In this work, the
modular nature of the genetic diseases [3,9] and the consistency
between the disease phenotypic overlap [10] and genetic overlap
[11] are fully exploited. For this purpose, the disease similarity
network and the protein-protein interaction network are
incorporated systematically and comprehensively in a simple
and compact manner to formulate the computation of the
prioritization scores. As for a single disease gene association score
function, both the similar diseases in the disease similarity
network and neighbouring genes in the protein-protein interac-
tion network are considered because of the modular nature of the
genetic diseases. What is more, all the association scores between
the similar diseases and neighbouring genes would be integrated
into the iterative computation of this single disease gene
association score. This is illustrated in Figure 1.
Our method is used to analyse disease-gene association data
from the Online Mendelian Inheritance in Man (OMIM) [12] and
to test, in the 10-fold cross-validation setting, the utility in
prioritizing genes for all the diseases with at least one known gene.
The performance of our method is evaluated in comparison to the
method PRINCE. Results show that our method outperforms
PRINCE significantly in the gene prioritization task. Our method
is also applied to the study of three multi-factorial diseases-Breast
Cancer, Alzheimer Disease and Diabetes Mellitus Type 2, for
which some novel causal genes and related disease subnetworks
are suggested.
This paper is structured as follows: In Section ‘‘Results’’, a
comparison of our method and PRINCE is first made with 10-
fold cross-validation. Then our method is further validated on
the three types of control data set, with its robustness also
evaluated. Finally, we perform a case study on three multi-
factorial diseases-Breast Cancer, Alzheimer Disease and
Diabetes Mellitus Type 2. In Section ‘‘Discussions and
Conclusions’’, the success and improvements of this method
are described, with further applications of this method also
discussed and prospected. In Section ‘‘Methods’’ we introduce
the principle of this method, the network construction, and the
iterative algorithm for the computation of the disease gene
association score.
Results
Materials and Implementation
The 1428 known disease-gene associations and the protein-
protein interactions used to create the disease gene association
matrix Adg0 and the protein-protein interaction network G,
respectively, are downloaded from Cipher’s website [13]. Accord-
ing to the declaration in Cipher [6], the disease-gene associations
are from the OMIM knowledge database [12], and the protein-
protein interactions from the Human Protein Reference Databa-
se(HPRD) [14]. The disease similarity data constructed by van
Driel et al. [10] are downloaded from MimMiner’s website [15].
All these data will be illustrated carefully later in the Section
‘‘Methods’’.
In this method, there are three parameters to be tuned: (1)
the threshold parameter b which is used to filter out the disease
similarity and the prior association score smaller than it, and is
set as ‘‘0.5’’; (2) a,w h i c hc o n t r o l st h er e l a t i v ei m p o r t a n c eo ft h e
prior information in the computation of the disease-gene
association scores. We choose ‘‘0.6’’ for it and the other values
above ‘‘0.6’’ can not improve the performance of the method;
and (3) the number of the iterations. a and b are tuned by the
performance of the algorithm in the cross-validation tests. The
iterative computation will stop by the mean square deviation of
the disease-gene association score matrix between the k th
iteration and the (kz1) th iteration. Once the mean square
deviation is not greater than 0.00001, the algorithm will be
stopped.
Our method has been implemented in MATLAB, and
PRINCE has been reimplemented on our input data sets. Their
parameters were also tuned in the cross-validation test, in which
the parameter c and d were tuned as 21414 and 528, respectively,
to get the best performance, and the relative importance of the
prior knowledge and the mean square deviation were set as the
same as those in our method.
All the computational experiments were executed on four cores
of Intel(R) Xeon(R) CPU E5504 @2.00Ghz.The MATLAB code
and data sets described herein are available upon request.
Precision, recall and irrelevant control set
According to the standard definitions of precision and recall in
Formula (1), which were given by Lage et al. [4].
Figure 1. Principle of our method. In Figure 1, green round nodes
represent proteins, and blue square nodes represent diseases, with
each dot line connecting a green round node and a blue square node
indicating a known disease-gene association. The red line connecting
gene g and disease d is a candidate disease-gene association remaining
to be estimated, which is measured by the associations indicated by
black dot line in this figure iteratively in our method.
doi:10.1371/journal.pone.0024171.g001
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the number of relevant items retrieved
the total number of items retrieved
recall~
the number of relevant items retrieved
the total number of relevant items
ð1Þ
For a given-rank threshold, precision is the fraction of the
relevant genes retrieved among all the genes retrieved (the number
of relevant genes retrieved/the number of genes retrieved) and
recall is the proportion of the relevant genes retrieved to all the
relevant genes in collection (the number of relevant genes
retrieved/the number of relevant genes). Here, the relevant genes
are considered as the known disease genes for each disease, and
the total number of items (genes) retrieved is the total number of
genes above the rank threshold.
To compute the precision and recall, the relevant items and
irrelevant items should be constructed. First and foremost, the
known disease-gene associations are relevant items here. As for the
irrelevant items, we associated the genes that are not known to any
disease with a disease artificially, and these disease-gene
associations are considered as irrelevant items and constitute the
irrelevant control set. It should be known that the genes, which are
not associated with any disease in our disease-gene association set
and called ‘‘unassociated genes’’, are not ‘‘irrelevant’’ and just
‘‘unknown to us’’. In our method, three types of irrelevant control
set are constructed. One is the whole genome wide control set,
another is the random control set and the last one is the artificial
linkage interval control set. As for the random control set in 10-
fold cross-validation, we divided all the 1428 disease-gene
associations into ten subdivisions averagely, with about 142
diseases and 142 disease-gene associations in each subdivision.
For each subdivision, we randomly selected n genes from the set of
‘‘unassociated genes’’. For each disease involved in the subdivision,
we constructed n disease-gene associations with the n random
selected genes. So, there are about 142   n disease-gene associa-
tions constructed artificially, which constitute the random control
set and are considered as irrelevant items. There are about 142
known disease-gene associations, which are considered as relevant
items. Both the irrelevant and relevant items are measured by their
ranks in the whole genome to compute precision and recall. All ten
subdivisions are done separately in the same way as above. For a
given rank k, the final precision and recall are the average results
of all ten subdivisions. As for the whole genome wide control set,
all the ‘‘unassociated genes’’ in the protein interaction network
rather than random selected n genes are used, and the irrelevant
items and the irrelevant control set are constructed in the same
way as above. As regard to simulating the real-life situation in
which one or more susceptible linkage intervals rather than
specific genes have been associated with some disease, an artificial
linkage interval around a known disease-causing gene is
constructed according to the genes’ coordinates on the whole
genome, and this is motivated by the method used in Lage et al.
[4]. We extracted no more than 100 genes around the known
disease gene on the same chromosome, and these genes are used to
construct the irrelevant items and the irrelevant control set as
above. The tests were performed on the three irrelevant control
sets, and the results will be described in detail later.
A comparison between our method and the method
PRINCE
Only a comparison was made between our method and the
state-of-the-art method PRINCE because in PRINCE both the
random-walk based method of [5] and the Cipher method [6]
were reimplemented and evaluated on the same input data. We
reimplemented the method PRINCE on our input data and made
the comparison with it. Our method was compared with PRINCE
by the 10-fold cross-validation procedure. In each test of 10-fold
cross-validation, 1/10 of the known associations in the disease-
gene association set were removed, each method being evaluated
by its success in recovering the hidden association. For a given-
rank threshold k, if the hidden disease-gene association was ranked
within the top k over the entire protein interaction network, it
could be said that the association was successfully recovered. The
two methods were evaluated in performance in terms of precision
versus recall when varying the rank threshold k.
The results obtained by prioritizing candidates on all 1126
diseases in the 10-fold cross-validation show that our method is
superior to PRINCE in both precision and recall (Figure 2). Of all
1126 diseases, in terms of 10-fold cross-validation on the random
control set of size 2000, there are 633 different predictions ranked
within top 10, among which there are 622 correctly identified
disease genes, so that the precision at this threshold is 98.3%. At
the same threshold, the recall is 43.6%. A plot of precision versus
threshold k shows the proportionality between the rank and the
chance that the candidate gene is the correctly identified disease
gene. Candidates ranked within top 100 are correct in more than
85.7% of the cases (Figure 3-a). That is, top ranked candidates are
very likely to be correct disease-causing genes. Another plot of
recall versus rank threshold k is depicted in Figure 3-b.
One type of failure to reconstruct the known disease gene
association should be recognized. In our method, the topological
correlation between the disease similarity network and the protein-
protein interaction network are considered fairly in combination
with the prior information on the disease-gene associations, and
as a result, the well-connected genes in the protein-protein
interaction network may tend to be top ranked.
Tests on three irrelevant control sets
Our method was tested on three types of irrelevant control set:
the whole genome wide control set, the random control set and the
artificial linkage interval control set. For the random control set,
we randomly selected two thousand or three thousand ‘‘unasso-
ciated genes’’ to construct the irrelevant control set and the
irrelevant items. The two other irrelevant control sets and
irrelevant items are constructed in the way as described above.
The 10-fold cross-validation tests were performed and the result
analysis was made on the three irrelevant control sets. The results
on the three types of control set are shown in Figure 4. Ranking
over the whole genome is of great importance because many
OMIM phenotypes have no causative genes till now. In terms of
the 10-fold cross-validation, our method is used to successfully
rank the known disease-causing gene as one of the top five from
the 8919 genes in the protein interaction network for 391 cases,
with a precision of 0.0548 obtained. It is natural that the
performance of our method for the whole genome control set
should be inferior to that for either the random control set or the
simulated interval control set because the former control set is
much larger than the other two. The method performed worse for
the simulated interval set than for the random control set, which
may be attributed to the incompleteness of protein-protein
interaction data. In the construction of the artificial linkage
interval control set, we chose the upstream and downstream 50
genes about the known disease gene on the same chromosome to
simulate the linkage interval, and at the same time these 100 genes
must be in the protein-protein interaction network. It can be
expected that the linkage analysis in combination with the system
Predicting Disease-Causing Genes
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24171Figure 2. Comparison in performance between our method and PRINCE. A comparison between our method and PRINCE. We can see that
our method gives a high precision as well as a fairly high recall, and this is superior to that from PRINCE.
doi:10.1371/journal.pone.0024171.g002
Figure 3. A plot of precision and recall versus threshold k of our method. Figure 3-a A plot of precision versus threshold k. Figure 3-b A plot
of recall versus threshold k, where k means that the gene was ranked within top k in our method.
doi:10.1371/journal.pone.0024171.g003
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give more powerful insights in identifying novel disease-causing
genes.
Robustness of Our Method
We tested our method, biased towards the disease similarity
information and the protein-protein interaction networks. We
randomly selected 1/5 the disease gene associations from our data
set and 1000 genes from the protein-protein interaction network,
and then added white Gaussian noise on 1/5 the disease similarity
data and the interactions among all the 1000 genes to test the
robustness of our method. In terms of the 10-fold cross-validation,
the method can give a precision of 0.053 and 0.049, respectively,
on the genome wide control set, and the precision degradation is
small compared with the original precision of about 0.055. The
results indicate that our method does not rely heavily on known
disease similarity information or that it is not biased towards the
better characterized genes heavily in the protein-protein interac-
tion network.
Case Study
To further demonstrate the power of our method, we proceeded
to execute our method on multifactorial disorders. Breast Cancer
(MIM:114800), Alzheimer Disease (MIM:104300), and Diabetes
Mellitus Type 2 (MIM:125853) were selected for case studies.
First, the ranks for the known disease genes or susceptibility factors
implicated in the three cases are listed in Table 1. Second, we
checked the top ranked candidate genes for these cases in the
protein-protein interaction network, and at the same time a
clustering algorithm called PageRankNibble [16] was performed
over the protein-protein interaction network to discover the
functional subnetworks. The clustering algorithm PageRankNib-
ble is based on the random walk and PageRank vector. For a given
starting protein in the protein-protein interaction network, a
subnetwork near the starting protein may be found, and the
computing time is proportional to the size of the subnetwork.
Because of this property the algorithm PageRankNibble was used
to discover the subnetworks (which are considered as functional
modules and may be disease associated subnetworks) near all the
known disease-causing genes. First we filter these subnetworks by
their sizes and the ranks of the genes in them, and then a web
server g:Profiler with default parameters [17,18] was used to
analyse these subnetworks. Some subnetworks are given as
examples in Figure 5. The genes and their ranks in these
subnetworks (Figure 5) are also listed in Table 2. The primary
input to the web server g:Profiler is a list of gene, protein, or probe
identifiers from any of the currently supported species [17]. Here
in our analysis a list of genes in every subnetwork was provided as
the input to g:Profiler. The typical output of g:Profiler is a set of
enriched functional terms. Every term is accompanied by the size
of the query and the term gene lists, their overlap and the
statistical significance (P-value) of such enrichment [17]. In our
analysis of the gene list in one subnetwork, we only focused on
biological processes, molecular functions, subcellular localisations
and pathways, and the number of genes annotated by the term
and the P-value of term enrichment are analyzed and summarized
later for each case study.
Results for Breast Cancer
The section on the overview of Breast Cancer (MIM:114480) in
OMIM gives a list of 23 susceptibility genes (January, 2011), which
are also characterized by the protein-protein interaction network.
The rank results of the genome-wide prioritization scores for the
known disease and susceptibility genes are listed in Table 1. Our
method assigned the No. 1 rank to the known disease genes in our
data and also high ranks to most of the known breast cancer
causative genes which are not in our data, with 15 of these 23
genes ranked in the top 300 of the ranked whole genome (Table 1),
and with 300 being a reasonable number for the high-resolution
single nucleotide polymorphism (SNP) association analysis of a
complex disease in human population [19].
Next, we inferred Breast Cancer-related subnetworks by a
clustering method PageRankNibble, with two of such subnetworks
shown in Figure 5(a). The ranks of the genes in such subnetworks
are also given in Table 2. We can see that the genes in such two
subnetworks are ranked within top 200, except the gene ALG9 in
the rightmost subnetwork of Figure 5(a). Also we examined the
gene function in terms of GO [20] annotations and KEGG [21]
pathway enrichment. This enrichment analysis is carried out on
the g:Profiler web server. The leftmost subnetwork in Figure 5(a)
Figure 4. The performance of our method for three types of control data set. The method was tested on the whole genome, random
control set and simulated interval data set.
doi:10.1371/journal.pone.0024171.g004
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phase of the meiotic cell cycle (p-value=1.08e-11), 7 of which are
related to DNA recombination (p-value=5.28e-14), 10 of which
respond to the DNA damage stimulus (p-value=7.27e-14), and 10
of which are associated with DNA repair (p-value=7.17e-15).
There are 8 proteins in the rightmost subnetwork, and the gene
MDC1 is skipped because of ambiguous hits in GO database. 6 of
7 are related to the response to DNA damage stimulus (p-
value=8.67e-10), 6 of 7 are correlated to DNA recombination (p-
value=2.10e-13), 6 of 7 are involved in DNA repair (p-
value=1.86e-10), and 5 of 7 genes are connected with double-
strand break repair (p-value=7.55e-12). All this agrees well with
the current knowledge on the breast cancer [22].
Results for Alzheimer Disease
The section on the overview of Alzheimer(MIM:104300) in
OMIM gives a list of 11 susceptibility genes (January, 2011), which
are also characterized by the protein-protein interaction network.
The rank results of the genome-wide prioritization scores for the
known disease and susceptibility genes are listed in Table 1. The
known disease genes in our data are top ranked, and high ranks
are also given to most of the known Alzheimer causative genes
which were not in our data, with 4 of these 11 genes ranked within
the top 300 of the ranked whole genome (Table 1).
We made the same clustering analysis for Alzheimer Disease.
We inferred Alzheimer related subnetworks, with one of such
subnetworks shown in Figure 5(b). The ranks of the genes in this
subnetwork are ranked within top 40, except for the gene
KCNIP4. In the result analysis of the g:Profiler on the subnetwork
in Figure 5(b), we can see that 5 of those genes are enriched in cell
death and its regulation, that 5 of them are related to membrane
protein intracellular domain proteolysis (p-value=2.76e-15), that
5 of them are involved in induction of apoptosis (p-value=2.23e-
07), that 4 of them are correlated to Alzheimer’s disease pathway
(p-value=4.15e-06), and that 4 of them are connected with Notch
signaling pathway (p-value=2.45e-08). Almost all the knowledge
agrees well with the current knowledge on Alzheimer Disease
[23,24].
Results for Diabetes Mellitus Type 2
The section on the overview of Diabetes Mellitus, Type 2
(MIM:125853) in OMIM gives a list of 20 susceptibility genes
(January, 2011), which are characterized by the protein-protein
interaction network. The rank results of the genome-wide
prioritization scores for the known disease-causing genes and
susceptibility genes are listed in Table 1. Our method assigned the
top ranked to the known disease genes in our data and also high
ranks to most of the known Diabetes Mellitus causative genes
which were not in our data, with 15 of these 20 genes ranked
within the top 300 of the ranked whole genome (Table 1).
The subnetworks related with Diabetes Mellitus, Type 2 were
discovered by PageRankNibble, with one of such subnetworks
shown in Figure 5(c). We ranked 9 of the genes in this subnetwork
within top 200, except for the gene FGF12. The g:Profiler web
server was also used in analyzing the gene set of this subnetwork in
terms of GO annotation and KEGG pathway. Results show that 7
of them are related to MAPK signaling pathway (p-value=9.91e-
10), that 7 of them are correlated to protein kinase binding (p-
value=2.57e-09), and that 6 of them are connected with
MAPKKK cascade; furthermore, 3 of them are responsible for
the MAP-kinase scaffold activity(p-value=1.93e-10), which agrees
well with the current knowledge of Diabetes [25,26].
Table 1. The ranks of known disease-causing or susceptibility genes for three cases on the whole genome.
Breast cancer (MIM:114480)
Gene Rank Gene Rank Gene Rank Gene Rank
BRCA1 1 BRCA2 3 PIK3CA 6 NCOA3 261
BRIP1 5 RAD51 2 NBN 4 RAD51C 6369
TP53 10 RB1CC1 6223 AR 13 STK11 166
CHEK2 21 CDH1 407 PPM1D 4732 PTEN 7
CASP8 409 TGFB1 1881 NQO1 763 AKT1 28
HMMR 5789 ATM 11 BARD1 58
Alzheimer Disease (MIM:104300)
Gene Rank Gene Rank Gene Rank Gene Rank
APP 1 PSEN2 2 ABCA2 7388 TF 1090
A2M 651 HFE 1267 LRP1 14 VEGF 2195
NOS3 809 TNF 2232 PSEN1 7
Diabetes Mellitus, Type 2 (MIM:125853)
Gene Rank Gene Rank Gene Rank Gene Rank
SLC2A4 6 TCF2 5 MAPK8IP1 7 KCNJ15 7019
IRS1 2 PPP1R3A 8 NEUROD1 3 PPARG 1002
INSR 1 IPF1 4 KCNJ11 200 HNF4A 193
AKT2 117 ENPP1 158 IL6 4490 PTPN1 22
GPD2 2894 TCF1 9 TCF7L2 593
In Table 1, both the known disease-causing genes and the susceptibility genes for three cases of Breast Cancer, Alzheimer Disease and Diabetes Mellitus Type 2 are
listed, altogether with the corresponding rank in the whole genome.
doi:10.1371/journal.pone.0024171.t001
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novel suggestions. We analyzed top-50 predictions in each case.
We checked whether our predicted genes were already found to
be involved in disease by searching for the online database or
scientific publications. All of the published disease-gene
associations that were not in our input data set were collected.
Table 2. The ranks of genes in candidate disease subnetworks.
Genes in Fig. 5(a) and their ranks
RAD52 112 DMC1 147 BCCIP 25 RAD54L 149 ERCC2 133
ATRX 145 C17orf28 144 RAD54B 121 RAD51AP1 148 RAD51 2
TREX1 108 RAD50 24 MRE11A 68 H2AFX 20 FANCD2 12
NBN 4 DCLRE1C 23 MDC1 17 ALG9 5758
Genes in Fig. 5(b) and their ranks
NCSTN 6 KCNIP4 104 APH1A 35 DOCK3 40 APH1B 36
ICAM5 28 PSENEN 37 PSEN2 2 METTL2B 39
Genes in Fig. 5(c) and their ranks
MAPK8IP3 97 MAP3K13 166 MAPK8IP2 98 MAP2K7 121 MAPK8IP1 7
DUSP16 120 FGF12 2464 KNS2 110 PAX2 162 15244/- 74
In Table 2, the genes in the candidate disease subnetworks (in Fig. 5) and their ranks are listed.
doi:10.1371/journal.pone.0024171.t002
Figure 5. Subnetworks involved in disease for three cases. Four examples of putative protein subnetworks associated with the three cases are
shown in Figure 5. The node in the figure represents the protein/gene, and the HPRD ID and gene symbol are given and separated by the slant ‘/’.
The two putative disease subnetworks in Figure 5-a were discovered for Breast Cancer. The putative disease subnetwork in Figure 5-b was associated
with Alzheimer Disease. The putative disease subnetwork in Figure 5-c was related to Diabetes Mellitus, Type 2.
doi:10.1371/journal.pone.0024171.g005
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in the recent OMIM database (January,2011) which ranked
within top 50 in our result, but not in our data set. As for the
Alzheimer Disease(MIM:104300), 5 novel genes within top 50 in
our predicted results were verified in the online OMIM
database. The gene LRP1 on chromosome 12 was studied with
t h eA l z h e i m e rD i s e a s eo n8 5 0p e r s o n sa tt h ea g eo fo v e r6 0b y
Farrer et al. [27]. A 480-kb region encompassing the IDE gene
was also investigated by Prince et al. [28] in relation to the
Alzheimer Disease; furthermore, the cerebellar expression levels
o fI D Ew e r em e a s u r e db yZ o ue ta l .[ 2 9 ] .T h es a m er e s u l t sw e r e
extracted for Diabetes Mellitus, Type 2, and 4 novel genes
which were ranked among top 50 were verified in the online
OMIM database.
We also computed the disease-gene association scores and
corresponding ranks between all the 8919 genes characterized by
the protein-protein interaction network and all the 5080 diseases
in the disease similarity data set.
Discussion
The success of our method can be attributed to a combination
of several aspects. First, the large-scale disease similarity
information is exploited. Second, which is more important,
the disease similarity network and the protein-protein interac-
tion network are coupled in a comprehensive and systematic
way for the definition of the disease-gene association score
function, and this is well in accord with the consistency between
disease phenotypic overlap and genetic overlap. On one hand,
the definition of disease-gene association score makes full use of
the information implicated in both disease similarities and
neighbouring genes comprehensively. On the other hand, not
only the noise in the disease similarity information but also the
self-loop in the protein-protein interaction network are consid-
ered in the computation of the disease-gene association scores.
Third, an iterative algorithm was designed for the computation
of the disease-gene association score matrix for all the diseases
and all the candidate genes in the protein-protein interaction
network.
Nevertheless, our method can be improved in the following
ways. First, this method relies on the protein-protein interaction
data which have a low coverage and a high false positive ratio, and
the information on the isolated proteins in the network can not be
exploited. In our protein-protein interaction data there are 57
isolated proteins which are known to be involved in some diseases.
Second, the current disease similarity measurement is imprecise
and subjective. It can be expected that this method would show
more power if we could know more complete and reliable protein-
protein interactions, together with a more standardized and
objective disease description [30].
Two potential applications of our method should be noticed.
First, the prioritization score for candidate genes can give some
suggestions for further investigation. Second, the prioritization
score can be exploited to identify disease-causing protein
subnetworks, which are valuable for the study of the multi-
factorial diseases, and this has been experienced successfully in
PRINCE and this method.
Methods
In this section, the principle of our method is illustrated first.
Then the construction of several networks is defined and
formulated. Finally, an iterative algorithm is designed for the
computation of disease-gene association scores.
Principle of the method
The observation that the genes implicated in the same or
similar diseases lie close to each other in the protein-protein
interaction network [1,2,3] has motivated the design of some
computational approaches for prioritizing candidate genes
involved in diseases. Our method is predicated on this simple
observation together with the modular nature of the genetic
diseases [3,9] and the consistency between the phenotypic
overlap [10] and genotypic overlap [11]. Here, when a candidate
gene is prioritized for a disease, we consider the correlation of the
two subnetworks separately induced by the neighbours of the
gene in the protein-protein interaction network and the
neighbours of the disease in the disease similarity network. That
is, a single association between a gene and a disease is formulated
iteratively by the correlation of the two subnetworks. This
constraint can also be described as the fact that a gene is likely to
be involved in a disease if the gene’s neighbours are associated
with the similar diseases. In our method, the association score
between disease d and gene g is formulated iteratively as the
weighted sum of all the existing association scores between the
neighbours of g and the diseases similar to d.A si nF i g u r e1 ,t h e
association between gene g and disease d is measured over all the
associations between g and d’s similar diseases, the associations
between g’s neighbours and d, and the associations between g’s
neighbours and d’s similar diseases. In this figure, g’s neighbours
are g1, g2, g3, g4, g5, g6,a n dg7,a n dd’s similar diseases are d1,
d2, d3, d4, d5,a n dd6. So, we compute the association score
between g and d based on the known disease-gene associations
iteratively as follows:
Adg½d,g ~Adg½d,g5 zAdg½d,g4 zDsim½d,d1 |Adg½d1,g 
zDsim½d,d2 |Adg½d2,g6 zDsim½d,d3 |Adg½d3,g5 
zDsim½d,d4 |Adg½d4,g3 zDsim½d,d5 |Adg½d5,g10 
zDsim½d,d5 |Adg½d5,g1 zDsim½d,d6 |Adg½d6,g 
So are the associations between d and g5, d and g4, d1 and g, d2
and g6, d3 and g5, d4 and g3, d5 and g1, d5 and g10, and d6 and g
computed in the same iterative way.
We define a disease-gene association matrix in favor of com-
puting and storing the association scores. The disease similarity
network and the protein-protein interaction network are also
constructed and incorporated into the formulation of the disease-
gene association matrix in a simple and compact manner of matrix
multiplication. As a result, an iterative algorithm is designed for
the computation of the disease-gene association matrix. All this
will be described in detail in the later part of this section.
Network Construction
Filtered Disease similarity network. In our method, the
disease similarity network is introduced, where the node in the
network represents a disease, the edge connecting two nodes
indicates that the two diseases are similar, and the weight of the
edge indicates to what extent the two diseases are similar. We
define a disease similarity matrix Psim to model this network, in
which Psim½i,j  is the similarity score between disease i and
disease j. These disease similarities spanning 5080 diseases in the
OMIM knowledge database were computed by van Driel et al.
[10] by the text mining technique. In their analysis, similarity
values in the range [0,0.3] were not informative, while the
similarities in the range [0.6,1] showed significant functional
similarity between corresponding diseases. So, in our method the
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than it, in order to purify the disease similarity network as much
as possible.
Extended Protein-Protein interaction network. The
protein-protein interaction network is modelled as matrix G,i n
which the value of G½i,j  indicates whether the interaction between
proteins i and j exists. The value ‘‘1’’ denotes that the interaction
exists, and ‘‘0’’ denotes that the interaction does not exist. In our
method, with regard to the association between disease d and gene
g, the associations between the diseases similar to d and the
neighbours of g, the associations between the diseases similar to d
and the neigbours of g, and the associations between d and the
neighbours of g all need to be considered. So, we extend the
protein-protein interaction network by adding the self-interactions
of all the proteins into the interaction network. As a result, g is a
pseudo neighbour of g itself and will be counted when considering
the neighbours of g, and this will be in favor of the iterative
computation in a simple and compact manner of matrix
multiplication. Here, the associations between d and neighbours
of g will be considered definitely because d is the disease which is
the most similar to itself, and that is true in the construction of the
disease similarity network (all the elements on the diagonal being
‘‘1’’).
Disease-Gene Association Network. We construct the
disease-gene association network as the one where the node in
the network can be either a disease or a gene and the weighted
edge connecting a disease and a gene indicates to what extent the
gene is involved in the disease. This network can also be regarded
as a bipartite graph. In our method the disease-gene association
network is expressed by a disease-gene association matrix Adg,i n
which the element Adg½i,j  stores the association score of gene j
and disease i indicating the association strength between the gene
and the disease. The matrix Adg is initialized with the prior
information on the disease-causing genes which are from the
online OMIM database [12]. If the gene is known to be
associated with the disease, the association score in the matrix is
set to be ‘‘1’’. With regard to the situation in which the disease q
is not known to be associated with the gene v, we deal with it in
the way motivated by PRINCE [8]: the association score between
q and v is defined as the similarity between the two diseases q and
p. Here p is chosen so carefully that p is not only the most similar
to q but also associated with the gene v in our dataset. To
eliminate the noise information brought about by disease
similarities, the parameter b is also used to filter out the
association score that is smaller than it.
Algorithm
The input of our method includes both the protein-protein
interaction network G(V,E),w h e r eV is the protein/gene set
and E i st h ep r o t e i n / g e n ei n t e r a c t i on set (‘‘protein’’ or ‘‘gene’’
will be used alternatively according to the context in the paper),
and the disease similarity network Psim(U,F),w h e r eU is the
disease set and F is the disease similarity set over every two
diseases in U. In our method, the disease-gene association
matrix Adg is defined over all the diseases in U and all the genes
in V in Formula (2):
Adg~Psim|Adg|G ð2Þ
To solve the disease gene association matrix Adg in Formula (2),
we design an iterative algorithm. With regard to the prior
information on the disease gene associations, the disease-gene
association matrix is defined at the iteration k as Formula (3):
Adgk~(1{a)|Psim|Adgk{1|Gza|Adg0 ð3Þ
In Formula (3), the disease-gene association matrix is initialized
as Adg0 by the prior knowledge of the disease-gene associations.
The parameter a[(0,1) gives the relative importance between the
constraints which are opposed by the assumption and the prior
information. The constraint part of Adg½i,j  at the iteration k is
defined as Formula (4):
Adg½i,j 
kz1~
X G jj
l~1
((
X Psim jj
k~1
Psim½i,k |Adg½k,l 
k)|G½l,j ) ð4Þ
where Adg½i,j  is computed based on the associations between k
and l, in which k is over all the diseases similar to i (including i)
and l is over all the neighbours of j (including j). The iterative
computation is similar in manner to that by PRINCE, and our
method considers all the associations related to the association (i,j)
systematically and comprehensively while PRINCE considers just
the information which will flow into the node j when querying the
disease i in one iteration.
The final score of each association is determined by the
constraints opposed by both the protein-protein interaction
network and the disease similarity network, and also by the prior
knowledge. The iterative computation is controlled by the mean
square deviation of the two neighbouring disease-gene association
score matrixes. All the tests on the simulated data sets and the real
data sets have shown that the iterative computation would
converge eventually.
Acknowledgments
We also like to thank Xiaoke Ma, Hui Xiao, Haitao Luo and Changning
Liu for their helpful advice and discussions.
Author Contributions
Conceived and designed the experiments: XLG LG. Performed the
experiments: XLG XFY CSW. Analyzed the data: XLG. Contributed
reagents/materials/analysis tools: XLG LG AGD YZ. Wrote the paper:
XLG.
References
1. Gandhi TKB, Zhong J, Mathivanan S, Karthick L, et al. (2006) Analysis of the
human protein interactome and comparison with yeast, worm and fly interaction
datasets. Nat Genet 2006 38: 285–293.
2. Oti M, Snel B, Huynen MA, Brunner HG (2006) Predicting disease genes using
protein-protein interactions. J Med Genet 43: 691–698.
3. Oti M, Brunner HG (2007) The modular nature of genetic diseases. Clinical
Genetics 71: 1–11.
4. Lage K, Karlberg EO, Storling ZM, Olason PI, Pedersen AG, et al. (2007) A
human phenome-interactome network of protein complexes implicated in
genetic disorders. Nat Biotech 25: 309–316.
5. Kohler S, Bauer S, Horn D, Robinson PN (2008) Walking the interactome for
prioritization of candidate disease genes. American journal of human genetics
82: 949–958.
6. Wu X, Jiang R, Zhang MQ, Li S (2008) Network-based global inference of
human disease genes. Mol Syst Biol 4: 189.
7. Wu X, Liu Q, Jiang R (2009) Align human interactome with phenome to identify
causative genes and networks underlying disease families. Bioinformatics 25: 98–104.
8. Vanunu O, Magger O, Ruppin E, Sholomi T, Sharan R (2010) Associating
genes and Protein Complexes with Disease via Network Propagation. PloS
Comput Biol 6(1): e1000641.
Predicting Disease-Causing Genes
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e241719. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, et al. (2007) The human
disease network. PNAS 104(21): 8685–8690.
10. van Driel MA, Bruggeman J, Vriend G, Brunner HG, Leunissen JAM (2006) A
text-mining analysis of the human phenome. Eur J Hum Genet 14: 535–542.
11. Rzhetsky A, Wajngurt D, Park N, Zheng T (2007) Probing genetic overlap
among complex human phenotypes. Proc Natl Acad Sci USA 104:
11694–11699.
12. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA (2002) Online
mendelian inheritance in man (omim), a knowledgebase of human genes and
genetic disorders. Nucl Acids Res 30: 52–55.
13. Cipher–Correlating protein interaction network and phenotype network to
predict disease genes–website. [http://bioinfo.au.tsinghua.edu.cn/cipher/].
Accessed 2010 Aug. 20.
14. Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, et al. (2004)
Human protein reference database as a discovery resource for proteomics.
Nucleic Acids Res 32: D497–501.
15. MimMiner–A Online Mendelian Inheritance in Man Mining Tool–website.
Available: [http://www.cmbi.ru.nl/MimMiner/suppl.html]. Accessed 2010
Aug. 25.
16. Anderson R, Chung F, Lang K (2006) Local graph partitioning using pagerank
vectors. Foundations of Computer Science, IEEE Computer Society, Los
Alamitos, CA, USA. pp 475–486.
17. Ju ¨ri R, Meelis K, Hedi P, Jaanus H, Jaak V (2007) g:Profiler - a web-based
toolset for functional profiling of gene lists from large-scale expriments. Nuc Aci
Res 35: w193–w200.
18. g:Profiler–a web server for functional interpretation of gene lists–website.
Available: [http://biit.cs.ut.ee/gprofiler/index.cgi]. Accessed 2011 Jan.23.
19. Gaulton KJ, Mohlke KL, Vision TJ (2007) A computational system to select
candidate genes for complex human traits. Bioinformatics 23: 1132–1140.
20. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene
Ontology: tool for the unification of biology. Nature Genetics 25: 25–29.
21. Ogata H, Goto S, Sato F, Fujibuchi W, Bono H, et al. (1999) KEGG: Kyoto
encyclopedia of genes and genomes. Necleic Acids Research 27(1): 29–34.
22. Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ, Devilee P (2007) Genetic
susceptibility for breast cancer: how many more genes to be found? Crit Rev
Oncol Hemat 63: 125–149.
23. Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, et al.
(2011) The role of clusterin, complement receptor 1, and phosphatidylinositol
binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal
fluid biomarker levels. Arch Gen Psychiatry 68(2): 207–13. [PubMed:
21304480].
24. Reitz C, Brayne C, Mayeux R, Medscape (2011) Epidemiology of Alzheimer
disease. Nat Rev Neurol. [Epub ahead of print] [PubMed: 21304480].
25. Huang YC, Lin JM, Lin HJ, Chen CC, Chen SY, et al. (2011) Genome-wide
Association Study of Diabetic Retinopathy in a Taiwanese Population.
Ophthalmology. [Epub ahead of print] [PubMed: 21310492].
26. Liang H, Zhong Y, Huang Y, Chen G (2011) Type 1 receptor parathyroid
hormone (PTH1R) influences breast cancer cell proliferation and apoptosis
induced by high levels of glucose. Med Oncol. [Online First] [PubMed:
21312071].
27. Farrer LA, Bowirrat A, Friedland RP, Waraska K, Korczyn AD, et al. (2003)
Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-
Arab community. Hum Molec Genet 12: 415–422. [PubMed: 12566388].
28. Prince JA, Feuk L, Gu HF, Johansson B, Gatz M, et al. (2003) Genetic variation
in a haplotype block spanning IDE influences Alzheimer disease. Hum Mutat
22: 363–371. [PubMed: 14517947].
29. Zou F, Carrasquillo MM, Pankratz VS, Belbin O, Morgan K, et al. (2010) Gene
expression levels as endophenotypes in genome-wide association studies of
Alzheimer disease. Neurology 74: 480–486. [PubMed: 20142614].
30. Biesecker LG (2005) Mapping phenotypes to language: a proposal to organize
and standardize the clinical descriptions of malformations. Clin Genet 68:
320–326.
Predicting Disease-Causing Genes
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24171